COMP <GO>
ABCL vs EWTX // NET PROFIT MARGIN
AbCellera Biologics Inc. (NASDAQ) VS. Edgewise Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ABCL 5
— EWTX 4
▲ NET PROFIT MARGIN LEADER: EWTX
LAST: $12.27 (-6.19%) • MKT CAP: $4.24B
net-margins
-60.00%
LAST: $38.90 (-0.03%) • MKT CAP: $4.23B
net-margins
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABCL VS. EWTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABCL | EWTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.50% | -31.90% | +11.40 | ABCL | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.11% | -3.41% | -0.70 | EWTX | /fcf-yield <GO> |
| Operating Margin | -60.00% | -16.20% | -43.80 | EWTX | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | 0.00% | -60.00 | EWTX | /net-margins <GO> |
| Revenue Growth (YoY) | 160.60% | -1.10% | +161.70 | ABCL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.60 | 26.00 | -19.40 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | ABCL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 45.8 | +3.15 | ABCL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.10 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 25.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.24B | $4.23B | $10.9M | ABCL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABCL REV | EWTX REV | ABCL GROSS % | EWTX GROSS % | ABCL FCF | EWTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $75.1M | $0 | — | — | -$174.1M | -$144.1M |
| FY 2024 | $28.8M | $0 | — | — | -$187.0M | -$110.3M |
| FY 2023 | $38.0M | $0 | — | — | -$43.9M | -$91.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABCL // BETA —
EWTX // BETA 1.10